PURPOSE: To provide a method for treating or preventing the abstinence syndrome against habit-forming drugs (specifically, alcohol- or opiate-based analgesic, a method for inhibiting or recurrence prevention from habitual use of or addiction to such drugs, and weakening/diminishing the tolerance to opiate-type drugs. CONSTITUTION: A relevant patient is administered with a curatively effective amount of a competitive NMDA (N-methyl-D-aspartate) receptor antagonist such as D-(-)(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carbxoylic acid, S-α- amino-5-phosphonomethyl-(1,1'-biphenyl)-3-propanoic acid, E-2-amino-4-methyl-5- phosphono-3-pentenoic acid, ethyl E-2-amino-4-methyl-5-phosphono-3-pentenoate or cis-4-phosphonomethyl-2-piperidinecarboxylic acid.
NOVEL USAGE OF COMPETITIVE NMDA RECEPTOR ANTAGONISTIC BODY